Risperidone and Pulmonary infarction - a phase IV clinical study of FDA data

Summary:

Pulmonary infarction is found among people who take Risperidone, especially for people who are male, 20-29 old, have been taking the drug for < 1 month.

The phase IV clinical study analyzes which people take Risperidone and have Pulmonary infarction. It is created by eHealthMe based on reports of 61,258 people who have side effects when taking Risperidone from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Feb, 07, 2023

61,258 people reported to have side effects when taking Risperidone.
Among them, 15 people (0.02%) have Pulmonary infarction.

What is Risperidone?

Risperidone has active ingredients of risperidone. It is often used in bipolar disorder. eHealthMe is studying from 62,590 Risperidone users for its effectiveness, alternative drugs and more.

What is Pulmonary infarction?

Pulmonary infarction (death of a small area of lung) is found to be associated with 1,010 drugs and 588 conditions by eHealthMe.

Number of Risperidone and Pulmonary infarction reports submitted per year:

Could Risperidone cause Pulmonary infarction?

Time on Risperidone when people have Pulmonary infarction *:

Gender of people who have Pulmonary infarction when taking Risperidone *:

female: 42.86 %
male: 57.14 %

Age of people who have Pulmonary infarction when taking Risperidone *:

Common drugs people take besides Risperidone *:

Fluoxetine: 5 people, 33.33%
Valium: 2 people, 13.33%
Yaz: 1 person, 6.67%
Lipitor: 1 person, 6.67%
Akineton: 1 person, 6.67%
Albuterol: 1 person, 6.67%
Amlodipine: 1 person, 6.67%
Atarax: 1 person, 6.67%
Citalopram Hydrobromide: 1 person, 6.67%
Cymbalta: 1 person, 6.67%

Common side effects people have besides Pulmonary infarction *:

Pulmonary Embolism (blockage of the main artery of the lung): 14 people, 93.33%
Pleural Effusion (water on the lungs): 4 people, 26.67%
Stress And Anxiety: 4 people, 26.67%
Chest Pain: 4 people, 26.67%
Deep Venous Thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis): 4 people, 26.67%
Cerebral Infarction (less blood supply to brain resulting tissue damage): 2 people, 13.33%
Large Intestinal Obstruction: 1 person, 6.67%
Bundle Branch Block Right (absence of transmission of electric impulses from the atrioventricular (av) bundle of his to the right ventricle): 1 person, 6.67%
Cardiac Failure: 1 person, 6.67%
Enlarged Prostate: 1 person, 6.67%

Common conditions people have *:

Delirium (wild excitement): 2 people, 13.33%
Confusion: 2 people, 13.33%
Type 2 Diabetes: 1 person, 6.67%
High Blood Cholesterol: 1 person, 6.67%
Autonomic Nervous System Imbalance (autonomic nervous system is of net equal emphasis): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Risperidone and have Pulmonary infarction?

Check whether Pulmonary infarction is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Janardhana P, Nagaraj AK, Basavanna PL, "Risperidone-induced skin rash", Indian journal of psychiatry, 2016 Jan .
Dsouza MC, "Could risperidone have caused the cataract?: A case report and review of literature", Journal of Research in Psychiatry and Behavioral Science, 2015 Jan .
Dsouza MC, "COULD RISPERIDONE HAVE CAUSED THE CATARACT", JRPBS, 2015 Jan .
Ray RK, Bashir MA, Rao S, "Co-Administration of Risperidone and Sodium Valproate Causing Bilateral Chronic Exertional Lower Leg Compartment Syndrome", Open Journal of Orthopedics, 2014 Apr .
Hosseini, S. H., & Ahmadi, A., "Peripheral edema occurring during treatment with risperidone combined with citalopram", Case reports in medicine, 2012 Jan .

Related studies

How severe was Pulmonary infarction and when was it recovered:

Pulmonary infarction in Risperidone

Expand to all the drugs that have ingredients of risperidone:

Pulmonary infarction and drugs with ingredients of risperidone

Alternative drugs to, pros and cons of Risperidone:

Risperidone (62,590 reports)

Common Risperidone side effects:

Browse all side effects of Risperidone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Pulmonary infarction treatments and more:

Pulmonary infarction (3,765 reports)

COVID vaccines that are related to Pulmonary infarction:

Common drugs associated with Pulmonary infarction:

Nuvaring: 671 reports
Yaz: 530 reports
Yasmin: 522 reports
Ibu: 218 reports
Ibuprofen: 216 reports
Prednisone: 149 reports
Albuterol: 103 reports
Drospirenone and ethinyl estradiol: 102 reports

All the drugs that are associated with Pulmonary infarction:

Pulmonary infarction (1,010 drugs)

Common conditions associated with Pulmonary infarction:

Birth control: 854 reports
Pain: 152 reports
Premenstrual syndrome: 149 reports
Acne: 148 reports
Depression: 117 reports

All the conditions that are associated with Pulmonary infarction:

Pulmonary infarction (588 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on risperidone (the active ingredients of Risperidone) and Risperidone (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.